(19)
(11) EP 3 218 397 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.04.2021 Bulletin 2021/14

(45) Mention of the grant of the patent:
24.02.2021 Bulletin 2021/08

(21) Application number: 15797815.6

(22) Date of filing: 13.11.2015
(51) International Patent Classification (IPC): 
C07K 16/10(2006.01)
(86) International application number:
PCT/US2015/060733
(87) International publication number:
WO 2016/077789 (19.05.2016 Gazette 2016/20)

(54)

NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE

NEUTRALISIERENDE ANTIKÖRPER GEGEN EBOLA VIRUS GLYKOPROTEIN UND DEREN VERWENDUNG

ANTICORPS NEUTRALISANTS CONTRE EBOLA GLYCOPROTEIN ET LEUR UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.11.2014 US 201462080094 P
03.12.2014 US 201462087087 P

(43) Date of publication of application:
20.09.2017 Bulletin 2017/38

(60) Divisional application:
21158309.1

(73) Proprietors:
  • The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
    Bethesda, MD 20852-7660 (US)
  • The United States Government, as represented by The Secretary of The Army
    Fort Detrick, MD 21702 (US)
  • Humabs Biomed S.A.
    6500 Bellinzona (CH)
  • Institute for Research in Biomedicine
    6500 Bellinzona (CH)

(72) Inventors:
  • CORTI, Davide
    CH-6500 Bellinzona (CH)
  • LANZAVECCHIA, Antonio
    CH-6500 Bellinzona (CH)
  • TREFRY, John
    MD 210702 (US)
  • SULLIVAN, Nancy
    MD 20892 (US)
  • MULANGU, Sabue
    MD 20892 (US)
  • GRAHAM, Barney
    MD 20892 (US)
  • MUYEMBE-TAMFUN, Jean-Jacques
    Kinshasa (CG)
  • LEDGERWOOD, Julie
    Bethesda, MD 20892 (US)
  • STANLEY, Daphne
    Bethesda, MD 20892 (US)

(74) Representative: Docherty, Robert Charles 
Symbiosis IP Limited York Biotech Campus Office 14FA05 Sand Hutton
York, YO41 1LZ
York, YO41 1LZ (GB)


(56) References cited: : 
WO-A2-2004/018649
 WO-A2-2011/071574
   
  • XIANGGUO QIU ET AL: "Characterization ofglycoprotein-specific monoclonal antibodies", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 141, no. 2, 13 August 2011 (2011-08-13), pages 218-227, XP028322702, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2011.08.008 [retrieved on 2011-08-31]
  • LEE J E ET AL: "Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it", CURRENT OPINION IN STRUCTURAL BIOLOGY, ELSEVIER LTD, GB, vol. 19, no. 4, 1 August 2009 (2009-08-01) , pages 408-417, XP026541929, ISSN: 0959-440X, DOI: 10.1016/J.SBI.2009.05.004 [retrieved on 2009-06-24]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).